Cell therapy (CAR-T) · Kills target cells, directed at ROR1 · developed by Lyell Immunopharma
LYL797 is an autologous CAR T-cell therapy targeting ROR1, a receptor tyrosine kinase-like orphan receptor expressed on certain tumor cells. The T-cells are genetically and epigenetically reprogrammed to overexpress c-Jun, enhancing resistance to exhaustion and durable anti-tumor activity. It is studied in triple-negative breast cancer, non-small cell lung cancer, and other advanced malignancies.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05274451 | Phase 1 | Triple Negative Breast Cancer | Terminated | LYEL |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Advanced Breast CancerAdvanced Lung CarcinomaNon Small Cell Lung CancerNon Small Cell Lung Cancer MetastaticNon-Small Cell Carcinoma of Lung, TNM Stage 4NSCLCNSCLC Stage IVNSCLC, RecurrentRecurrent Breast CancerRecurrent NSCLCRelapse/RecurrenceRelapsed CancerTNBC - Triple-Negative Breast CancerTriple Negative Breast Cancer
Updated Oct 3, 2026. Something wrong or missing? Report it on the LYEL page.
See LYEL's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
LYEL catalysts and pipeline →